Health checks Understand your health

Tumour markers AFP, CEA, CA-125 and PSA: what they are and who should test

What the tumour markers in health check packages can and cannot tell you, why a high value doesn't mean cancer, and who benefits from testing.

About 6 min read

Prepared by Mongkhondee Clinic · Our editorial standards

Blood sample tubes for laboratory testing
Editorial image

Tumour markers make a health check package look complete and reassuring, and they also cause the most unnecessary worry. A slightly raised value can come from many ordinary causes, and a normal value doesn't guarantee there is no cancer. Below is who these tests are for.

Key takeaways

  • Tumour markers can assist diagnosis, treatment planning and follow-up in selected settings; they are not a general cancer-screening panel for everyone.
  • Values rise with hepatitis, smoking, periods, an enlarged prostate or inflammation, while many early cancers show normal values.
  • Liver-cancer surveillance requires risk-based eligibility, not merely any hepatitis infection. PSA screening requires discussion of benefits and harms.
  • Other screening, such as cervical, breast or colorectal screening, depends on age and risk; tumour markers do not replace those tests.

What a tumour marker is

Tumour markers may be measured in blood or tissue and arise from cancer cells or the body’s response. Some rise in non-cancer conditions, while some cancers produce normal results. Interpretation needs history, examination and sometimes imaging or biopsy. Uses include selected diagnosis, treatment selection and follow-up; one blood panel cannot detect every cancer.

Sources: [1] National Cancer Institute, U.S. National Institutes of Health

The four found in packages

Blood sample tubes for laboratory testing
Health checksBlood sample tubes for laboratory testing

Scroll sideways to read the full table →

The four found in packages
MarkerLinked cancersOther causes of a high valueWho benefits from testing
AFPLiver and some germ-cell cancersLiver disease and other conditionsWith ultrasound for eligible liver-cancer surveillance, or another clinician-defined indication
CEAFollow-up of selected cancers, including colorectal cancerNon-cancer conditions can increase itA treating clinician’s plan; not a standalone general screen
CA-125Selected ovarian-cancer assessment and follow-upNon-cancer conditions can increase itClinical assessment with other information; family history alone does not mandate testing
PSAProstate assessment and cancer follow-upBenign enlargement or inflammationU.S. USPSTF: individual screening decision at 55–69; no routine screening from 70

Sources: [1] National Cancer Institute, U.S. National Institutes of Health, [2] U.S. Preventive Services Task Force, [3] สมาคมโรคตับแห่งประเทศไทย

Does a high value mean cancer?

A raised result does not establish cancer, and a normal result does not exclude it. Testing without an indication can lead to repeat tests, imaging or biopsy, with risks, costs and anxiety. One cutoff or one result is not a diagnosis.

If symptoms or an abnormal result are present, seek appropriate evaluation. A normal tumour-marker result is not a reason to postpone indicated screening.

Good to know: If you've already been tested and a value is high, don't panic. Bring the result to a doctor to assess symptoms and history, and repeat or add tests as appropriate. One value is not a diagnosis.

Sources: [1] National Cancer Institute, U.S. National Institutes of Health, [2] U.S. Preventive Services Task Force

So who should test?

Blood pressure being measured
Health checksBlood pressure being measured
  • Liver cancer: the 2021 Thai guideline identifies risk groups including surveillance-eligible cirrhosis, selected chronic HBV by age/sex or first-degree family history, and HCV with advanced fibrosis. A clinician must confirm current eligibility, tests and intervals; AFP every six months is not a rule for every infected person.
  • PSA: U.S. USPSTF recommends an individual decision for asymptomatic men aged 55–69 and recommends against routine screening at 70 or older. Discuss false positives, biopsy, overdiagnosis and overtreatment. This is not a prohibition on investigating symptoms.
  • Family history may require risk assessment or referral; it does not justify every tumour marker.
  • Unexplained weight loss, persistent bloating, urinary changes or other new symptoms require assessment, not a tumour-marker package in place of evaluation.

Sources: [1] National Cancer Institute, U.S. National Institutes of Health, [2] U.S. Preventive Services Task Force, [3] สมาคมโรคตับแห่งประเทศไทย

Who is the clinic's Plan C for?

Plan C costs 4,400 baht and adds tests to Plan B, including several tumour markers. An indication for one test does not justify the whole panel, and wanting a test does not prove benefit. Discuss indications and harms individually, or choose specific tests. See the current plan comparison and risk-based check-up guide.

Sources: [1] National Cancer Institute, U.S. National Institutes of Health

Frequently asked questions

For people without risk factors the evidence doesn't support it: sensitivity is low in early disease and false positives are common. Screening proven to reduce deaths is cervical screening, mammography and bowel cancer screening.

Related services

Related articles

Sources

  1. [1] Tumor Markers National Cancer Institute, U.S. National Institutes of Health
  2. [2] Prostate Cancer: Screening U.S. Preventive Services Task Force
  3. [3] Thai hepatocellular carcinoma guideline (2021), surveillance recommendations 12–18 สมาคมโรคตับแห่งประเทศไทยAccessed 12 October 2026

This content is general information and does not replace an examination, diagnosis or personal advice from a doctor. Published 21 September 2026

How we select sources and handle corrections

Everyone's health is different

If you have a health condition, take regular medication, are pregnant or have unusual symptoms, let a doctor assess you first. Message us on LINE.